Your browser doesn't support javascript.
loading
Gynecomastia associated with calcium channel blocker therapy.
Tanner, L A; Bosco, L A.
Afiliação
  • Tanner LA; Division of Epidemiology and Surveillance, Food and Drug Administration, Rockville, Md.
Arch Intern Med ; 148(2): 379-80, 1988 Feb.
Article em En | MEDLINE | ID: mdl-3341839
ABSTRACT
Gynecomastia is a reaction that is not usually associated with calcium channel blocker therapy. The Division of Epidemiology and Surveillance, within the US Food and Drug Administration (Rockville, Md), has received 31 reports of gynecomastia occurring after the use of these drugs. The underlying mechanism of this reaction is unknown, although two patients did report elevated prolactin levels. Gynecomastia developed in two patients, resulting in the surgical removal of the breast and/or nodules before discontinuation of drug therapy. The possibility of an association between calcium channel blockers and gynecomastia should be considered before an extensive workup or surgical procedure is undertaken.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bloqueadores dos Canais de Cálcio / Ginecomastia Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 1988 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bloqueadores dos Canais de Cálcio / Ginecomastia Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 1988 Tipo de documento: Article